Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of Romidepsin in Combination With Parsaclisib in Relapsed and Refractory T-Cell Lymphomas

NCT04774068 is registered in ClinicalTrials.gov with Walter Hanel as lead sponsor.

NCT NCT04774068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04774068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of Romidepsin in Combination With Parsaclisib in Relapsed and Refractory T-Cell Lymphomas
Lead sponsor
Walter Hanel
Phase
Phase 1
Overall status
Completed
Start date
September 1, 2021
Completion date
October 27, 2024
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent anaplastic large cell lymphoma, recurrent mature t-cell and nk-cell non-hodgkin lymphoma, recurrent primary cutaneous t-cell non-hodgkin lymphoma, recurrent transformed mycosis fungoides, refractory anaplastic large cell lymphoma, refractory mature t-cell and nk-cell non-hodgkin lymphoma, refractory primary cutaneous t-cell non-hodgkin lymphoma, refractory transformed mycosis fungoides, t-cell non-hodgkin lymphoma